Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
| 11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
| 9/21/2023 | $28.00 | Overweight | Barclays |
| 3/16/2023 | $33.00 | Outperform | Raymond James |
| 10/14/2022 | $27.00 → $25.00 | Neutral → Underperform | BofA Securities |
| 9/6/2022 | $37.00 → $34.00 | Neutral → Overweight | Piper Sandler |
| 8/5/2022 | $40.00 → $37.00 | Buy → Neutral | BofA Securities |
| 4/27/2022 | $40.00 | Buy | Goldman |
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE:OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/
Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously
Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously
Barclays initiated coverage of Organon with a rating of Overweight and set a new price target of $28.00
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and
Full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency Full year 2024 diluted earnings per share of $3.33 and non-GAAP Adjusted diluted earnings per share of $4.11 Full year 2024 Adjusted EBITDA of $1.96 billion inclusive of $81 million of IPR&D, representing a 30.6% Adjusted EBITDA margin Full year 2025 financial guidance ranges provided Full year revenue range of $6.125 billion - $6.325 billion, inclusive of an approximate $200 million year-over-year negative impact from foreign exchange Adjusted EBITDA margin range of 31.0% - 32.0% Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 202
Organon (NYSE:OGN), a global healthcare company with a focus on women's health, will release its fourth quarter and full year 2024 financial results on February 13, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EST. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon's fourth quarter and full year 2024 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2024 Financia
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
10-K - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel
Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk
Organon Canada launches 'HER Professional Journey' to support female employees to navigate their career paths, and announces a new commitment to funding menopause-related education KIRKLAND, QC, March 8, 2024 /CNW/ - On International Women's Day, Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, launches HER Professional Journey and is encouraging businesses in Canada to Invest in HER and address the unique health experiences that women face, including in the workplace, so that women can feel supported and empowered at every stage of their career.